Low risk patient RCT for HC
Q+AZ and HC
Q vs. control, not showing any significant differences.
Authors note that the results are not applicable to higher risk patients; that positive PCR may simply reflect detection of inactive (non-infectious) viral remnants; that an alternative dosage regimen may be more effective; and that medication adherence was unknown.
Q dosing was 600mg/day for 1 week, therapeutic levels may not be reached for several days. There were no deaths or serious adverse events.
hospitalization, ↓12.5%, p=1.00, HCQ+AZ or HCQ vs. control risk of hospitalization
no recovery, ↓25.8%, p=0.58, HCQ+AZ or HCQ vs. control risk of symptomatic at day 21
no virological cure, ↑10.3%, p=0.13, HCQ+AZ or HCQ vs. control risk of Ct<=40 at day 14